Abstract |
CP-122,288 is a highly potent inhibitor of neurogenic plasma extravasation in animal models at doses without vasoconstrictor effect. We evaluated the acute antimigraine efficacy of intravenous and oral CP-122,288 in two double-blind studies. In a crossover design, patients randomly received 31.25 microg of CP-122,288 intravenously, placebo, or both. In the oral study, patients received placebo or one of four doses of CP-122,288 between 3.125 and 312.5 microg, using a novel "up and down" design for randomization. Both studies were stopped prematurely when target efficacy could not be achieved. Responder rates were 29% for CP-122,288 versus 30% for placebo (difference, -1%; 95% CI, -24-22%; intravenous study) and an overall rate of 25% for CP-122,288 versus 0% for placebo (difference, 25%; 95% CI; 10-40%; oral study). CP-122,288 was not clinically effective at doses and plasma concentrations in excess of those required to inhibit neurogenic plasma extravasation in animals. Neurogenic plasma extravasation is unlikely to play a crucial role in the pathophysiology of migraine headache.
|
Authors | K I Roon, J Olesen, H C Diener, P Ellis, J Hettiarachchi, P H Poole, I Christianssen, D Kleinermans, J G Kok, M D Ferrari |
Journal | Annals of neurology
(Ann Neurol)
Vol. 47
Issue 2
Pg. 238-41
(Feb 2000)
ISSN: 0364-5134 [Print] United States |
PMID | 10665496
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Placebos
- Pyrrolidines
- Serotonin Receptor Agonists
- CP 122288
- Sumatriptan
|
Topics |
- Administration, Oral
- Adolescent
- Adult
- Aged
- Cross-Over Studies
- Double-Blind Method
- Female
- Humans
- Injections, Intravenous
- Male
- Middle Aged
- Migraine Disorders
(drug therapy)
- Neurogenic Inflammation
(prevention & control)
- Placebos
- Pyrrolidines
(administration & dosage, therapeutic use)
- Serotonin Receptor Agonists
(administration & dosage, therapeutic use)
- Sumatriptan
(administration & dosage, analogs & derivatives, therapeutic use)
- Treatment Failure
|